Swiss drugmaker shaping modern medicine
Anthropic has built a wet lab in the San Francisco Bay Area to accelerate biology work, confirming a shift from in silico research to real-lab experimentation. The move comes amid warnings about AI risks and a looming IPO, with leadership stressing safety while pursuing faster drug development.
Late-stage trials show sacituzumab tirumotecan improves median overall survival to 19 months versus 12.1 months with chemotherapy, but with notable side effects. New ovarian cancer therapy rinatabart sesutecan also demonstrates a strong progression-free survival benefit. Other programs in the field report positive results, signaling a robust biotech landscape but with continued safety concerns.
England launches STRIDE-RCT, a government-funded trial offering blood-based tests to 45-plus patients at about 200 GP surgeries to detect abdominal cancers early. The study will assess accuracy and determine if tests can guide urgent investigations for prostate, ovarian, bowel, pancreatic, stomach, liver and other cancers.
Anthropic is pitching its Claude models as a catalyst for rapid biological discovery, framing AI as a force to accelerate drug research. Its S-1 highlights life-sciences ambitions and partnerships with pharma giants while Isomorphic Labs is pursuing AI-designed medicines, aiming to design drugs without traditional lab work.